JP Morgan Chase
LOXO

JP Morgan Chase’s Loxo Oncology, Inc LOXO Stock Holding History

JP Morgan Chase’s Portfolio LOXO Stock Details LOXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100,728
Closed -$14.1M – 6235
2018
Q4 		$14.1M Sell
100,728
-68,180
-40% -$10.3M ﹤0.01% 1749
2018
Q3 		$28.9M Buy
168,908
+112,366
+199% +$18.9M 0.01% 1374
2018
Q2 		$9.81M Sell
56,542
-831
-1% -$125K ﹤0.01% 2159
2018
Q1 		$6.62M Sell
57,373
-8,058
-12% -$857K ﹤0.01% 2342
2017
Q4 		$5.51M Buy
65,431
+57,231
+698% +$4.77M ﹤0.01% 2611
2017
Q3 		$763K Sell
8,200
-46,600
-85% -$3.62M ﹤0.01% 3648
2017
Q2 		$4.39M Buy
54,800
+2,400
+5% +$133K ﹤0.01% 2559
2017
Q1 		$2.21M Sell
52,400
-43,604
-45% -$1.8M ﹤0.01% 2977
2016
Q4 		$3.08M Buy
96,004
+19,137
+25% +$491K ﹤0.01% 2805
2016
Q3 		$2.01M Buy
76,867
+14,006
+22% +$366K ﹤0.01% 2799
2016
Q2 		$1.46M Buy
62,861
+62,146
+8,692% +$1.55M ﹤0.01% 2969
2016
Q1 		$20K Buy
715
+191
+36% +$4K ﹤0.01% 4095
2015
Q4 		$15K Buy
+524
New +$14.1K ﹤0.01% 4134
2015
Q3 		– Sell
-166,000
Closed -$2.99M – 4185
2015
Q2 		$2.99M Buy
+166,000
New +$2.27M ﹤0.01% 2680

Other funds holding LOXO

IUHSA
Itau Unibanco Holding S.A. Sao Paulo, Brazil $4.31B AUM 46.57% 1-Year Est. Return

JP Morgan Chase's LOXO Position: Q1 2019 in Review

JP Morgan Chase sold out of Loxo Oncology, Inc (LOXO) in Q1 2019, closing a stake of 100,728 shares — an estimated $14.1M sold.

JP Morgan Chase first reported a position in LOXO in Q2 2015 and held it in 14 quarters. The position peaked at $28.9M in Q3 2018. 1 fund tracked by Wall St. Rank holds LOXO as of Q1 2019.

  • JP Morgan Chase reported no remaining Loxo Oncology, Inc position as of Q1 2019 after selling out during the quarter.
  • JP Morgan Chase sold 100,728 Loxo Oncology, Inc shares in Q1 2019, an estimated $14.1M.
  • JP Morgan Chase first reported a position in Loxo Oncology, Inc in Q2 2015 and held it in 14 quarters.
  • JP Morgan Chase's Loxo Oncology, Inc position peaked at $28.9M in Q3 2018.
  • 1 fund tracked by Wall St. Rank held Loxo Oncology, Inc as of Q1 2019.

Based on JP Morgan Chase's 13F filing for Q1 2019, filed 7 May 2019.